Related Experiment Video

Updated: Jul 5, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells

H Makkonen1, T Jääskeläinen, T Pitkänen-Arsiola

  • 1Institute of Biomedicine/Medical Biochemistry, University of Kuopio, Kuopio, Finland.

Oncogene
|May 13, 2008
PubMed

Insights

E twenty-six-like transcription factor 4 (ELK4) is a novel androgen receptor (AR) target gene in prostate cancer. Androgens may drive prostate cancer growth by increasing ELK4 levels, a key transcription factor.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Androgen receptor (AR) signaling is crucial in prostate cancer (PCa) development.
  • Identifying critical AR target genes in PCa remains a significant challenge.

Purpose of the Study:

  • To identify and characterize novel AR target genes involved in prostate cancer.
  • To elucidate the role of E twenty-six-like transcription factor 4 (ELK4) in AR-mediated prostate cancer progression.

Main Methods:

  • In-silico screening for AR response elements (AREs) in the ELK4 gene promoter.
  • In vitro binding assays and transcription assays to validate ARE function.
  • Chromatin immunoprecipitation (ChIP) to confirm AR and RNA polymerase II binding in vivo.
  • Quantitative analysis of ELK4 expression in prostate cancer tissues and cell lines.
  • RNA interference (RNAi) to assess the effect of ELK4 knockdown on cell growth.

Main Results:

  • ELK4 was identified as a novel AR target gene in human prostate cancer cells.
  • Specific AREs (ARE1 and ARE2) within the ELK4 promoter bound AR, with ARE2 being critical for androgen-induced activation in cooperation with FOXA1.
  • ChIP assays confirmed holo-AR and RNA polymerase II recruitment to the ELK4 promoter.
  • ELK4 expression is significantly elevated in prostate cancers, particularly in androgen-refractory tumors.
  • Reducing ELK4 levels via RNAi inhibited prostate cancer cell growth.

Conclusions:

  • ELK4 is a direct transcriptional target of the androgen receptor in prostate cancer cells.
  • Androgen-driven ELK4 upregulation contributes to prostate cancer growth and progression.
  • ELK4 represents a potential therapeutic target for advanced prostate cancer.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: